Abstract
Background
Gastric intestinal metaplasia (GIM) is an accepted pathologic precursor to gastric adenocarcinoma (GAC). While surveillance of GIM in Europe and Asia is common, only limited recommendations related to endoscopic surveillance of GIM exist in the United States.
Aim
To understand the clinical practice patterns of US gastroenterologists in the management and endoscopic surveillance of GIM.
Methods
A 23 item survey was developed to explore endoscopists’ opinions regarding the surveillance of GIM and knowledge of current guidelines. Eight clinical vignettes were developed to address specific clinical scenarios where endoscopic surveillance of GIM might be considered.
Results
There were 227 respondents, with 60 % working primarily in the private sector and 40 % in academic medicine. While 68 % of the respondents refer to major society guidelines for guidance in patient management, almost 78 % of endoscopist responders believe that there are no specific US guidelines pertaining to surveillance of GIM. Only two-thirds of respondents believe that based on current data, patients at increased risk of GAC should be a part of an endoscopic surveillance program, while 15 % believe all patients with GIM should receive endoscopic surveillance. Respondents use a wide range of biopsy techniques and surveillance intervals for patients with GIM, with no consistent pattern of practice identified.
Conclusions
There is variability in the knowledge and practice patterns of US endoscopists related to surveillance of gastric intestinal metaplasia. In the absence of detailed US GI society guidelines, many endoscopists perform surveillance endoscopy on patients with GIM using variable biopsy techniques and surveillance intervals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.Abbreviations
- GIM:
-
Gastric intestinal metaplasia
- GAC:
-
Gastric adenocarcinoma
- EGD:
-
Esophagogastroduodenoscopy
References
Vannela L, Lahner E, Osborn J, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther. 2010;31:1042–1050.
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48:3554–3560.
Rugge M, Capelle L, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–223.
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.
de Vries AC, Kuipers EJ. Epidemiology of premalignant gastric lesions: implications for the development of screening and surveillance strategies. Helicobacter. 2007;12:22–31.
Cho Y, Chung IK, Kim J, et al. Risk factors of developing interval early gastric cancer after negative endoscopy. Dig Dis Sci. 2014;60:936–943.
Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol. 2010;105:493–498.
Kim GH, Bang SJ, Ende AR, Hwang JH. Is screening and surveillance for early detection of gastric cancer needed in Korean Americans? Korean J Intern Med. 2015;30:747–758.
Hamashima C, Shibuya D, Yamzaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38:259–267.
Zullo A, Hassan C, Romiti A, et al. Follow-up of intestinal metaplasia in the stomach: when, how and why. World J Gastrointest Oncol. 2012;15:30–36.
Choi IJ. Gastric cancer screening and diagnosis. Korean J Gastroenterol. 2009;54:67–76.
Dinis-Ribeiro M, Areia M, de Vries A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP) and the Soceidade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy. 2012;44:74–94.
Hirota W, Zuckerman M, Adler D, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006;63:570–580.
Evans J, Chandrasekhara V, Chathadi K, et al. ASGE guideline: the role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82:1–8.
Surveillance, Epidemiology, and End Results (SEER) Program (http://seer.cancer.gov/statfacts/html/stomach.html). National Cancer Institute, 1992–2012. Accessed May 29, 2015.
Surveillance, Epidemiology, and End Results (SEER) Program (http://seer.cancer.gov/statfacts/html/esophagus.html). National Cancer Institute, 1992–2012. Accessed May 29, 2015.
Spechler S, Sharma P, Souza R, et al. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.
Wang K, Sampliner R. Updated guidelines 2008 for the diagnosis, surveillance, and therapy for Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797.
Hvid Jensen F, Pedersen L, Drewes A, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–1383.
de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952.
Frye J, Gomez J, Bliebel W, et al. Lack of consensus regarding management of gastric intestinal metaplasia among practicing gastroenterologists indicates a need for societal guidelines [abstract]. Gastrointest Endosc. 2013;77:261–262.
Frye J, Sauer B, Gomez J, et al. Gastroenterologists lack consensus regarding, if, how and when to screen or survey for premalignant gastric lesions: results of a pilot survey [abstract]. Am J Gastroenterol. 2012;107:S43–S44.
Pandey R, Millar A. Management of gastric intestinal metaplasia in the UK: a preliminary survey [abstract]. Gut. 2011;60:A105.
Uedo N, Ishihara R, Iishi H, et al. A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. Endoscopy. 2006;38:819–824.
Capelle LG, Haringsma J, de Vries AC, et al. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Dig Dis Sci. 2010;55:342–348.
Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology. 2005;129:1807–1808.
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointes Endosc. 2010;71:1150–1158.
Acknowledgments
This material is the result of work supported with resources at the Dallas VA Medical Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Additional information
Disclaimer: The contents do not represent the views of the US Department of Veterans Affairs or the United States Government.
Rights and permissions
About this article
Cite this article
Vance, R.B., Kubiliun, N. & Dunbar, K.B. How Do We Manage Gastric Intestinal Metaplasia? A Survey of Clinical Practice Trends for Gastrointestinal Endoscopists in the United States. Dig Dis Sci 61, 1870–1878 (2016). https://doi.org/10.1007/s10620-016-4107-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-016-4107-4